An inhaled COVID-19 vaccine would go directly to where the body would use it: the mucosal surface of the airways. This could mean less waste and more benefit, lower costs and reduced side-effects.
Academic rigour, journalistic flair
Articles on Vaccine development
Displaying 1 - 20 of 64 articles
A new network of public clinical trials institutes is urgently needed to replenish the empty pipeline for new antibiotics.
Various strategies are being pursued to boost worldwide vaccine coverage.
It sounds too good to be true, a vaccine that can protect against future virus variants. But governments around the world are keen to learn more.
Increasing skills and the availability of raw materials would be a bigger boost for vaccine production right now.
Skyrocketing demand coupled with shortages of vital components is leading to bottlenecks in the supply chain of Pfizer’s and other mRNA vaccines.
The R21 vaccine protected three-quarters of children against malaria in trials.
We have two mRNA COVID-19 vaccines so far. But what else can this technology do?
The development of the COVID-19 vaccines is part of a vast system of public subsidies and universities, not corporate ambition.
You need a new shot every year because current flu vaccines provide limited and temporary protection. But researchers’ new strategy could mean a one-and-done influenza vaccine is on the way.
Tuberculosis is a global threat and a public health concern on a scale similar to COVID-19.
What normally takes decades has been achieved in 12 months, without cutting corners.
The coronavirus vaccine was developed faster than any vaccine in history. It took just 332 days from the first sequencing of the virus genome to the first vaccines given to the public.
We should applaud drug companies for developing COVID-19 vaccines in record time, but let’s not be under any illusion about the profits that are motivating them.
In the disturbing scenario of human-to-mink-to-human COVID-19 transmission, the virus may mutate in mink prior to re-infecting people. That possibility makes vaccine design even more crucial.
The recent vaccine trial results certainly look impressive, but here’s how to fully interrogate what they mean.
Any COVID-19 vaccine is likely to be given first to higher risk groups before it is given to children. But we still need vaccines that are safe and effective for them too.
Experts from across The Conversation look at how COVID-19 vaccines will work, how they’re being tested and manufactured, and what challenges there will be to rolling them out.
New Zealand has entered several international agreements to access COVID-19 vaccines, but it should also amend domestic patent law and regulatory processes to prevent delays and costly negotiations.
With lives depending on a vaccine, trust in Canada’s COVID-19 Vaccine Task Force is crucial. Members of the task force need to make any industry links or potential conflicts of interest publicly clear.
Job Board
-
Lecturer/Senior Lecturer in Marketing (Brand Management/Marketing Communications)
-
PhD Research Awards in Basic Medical Research
-
Project Team Manager
-
Postdoctoral Research Fellow
-
Academic Lead (Work Integrated Learning)
Top contributors
-
Professor of Immunology and Associate Dean, Research and Graduate Studies, University of Guelph
-
Associate Professor of Viral Immunology, Department of Pathobiology, University of Guelph
-
Associate professor, UNSW Sydney
-
Professor Emeritus of Health Policy and Management, York University, Canada
-
Ph.D. Candidate in Chemical & Physical Biology, Vanderbilt Vaccine Center, Vanderbilt University
-
Ph.D. Student in Microbiology and Immunology, Vanderbilt Vaccine Center, Vanderbilt University
-
Reader in Bioethics and University Ethics Advisor, University of Portsmouth
-
Professor Emerita of Biology, Indiana University
-
Vaccine Knowledge Project Manager, University of Oxford
-
Vice-Chancellor's Research Fellow, School of Health and Biomedical Sciences, RMIT University
-
Professor of Immunology, RMIT University
-
Infectious Diseases Specialist and Clinical Professor, University of Tasmania
-
Senior Project Manager, Jenner Institute, University of Oxford
-
Associate Professor and ARC Future Fellow, The University of Western Australia
-
Clinician-scientist, Laboratory Medicine and Pathobiology, University of Toronto
